Prostate cancer drug darolutamide under safety watch in korea
NCT ID NCT06334120
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study monitors the safety and effectiveness of darolutamide (Nubeqa) in 600 Korean men with non-metastatic or metastatic hormone-sensitive prostate cancer. Participants receive the drug as part of their normal care and are followed for one year. Researchers track side effects and how well the drug controls the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
darolutamide (Nubeqa)
What this could lead to
If successful, this study will confirm that darolutamide is safe and works well for Korean men with certain types of prostate cancer.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It only includes Korean patients, so findings may not apply to other groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Multiple locations
RECRUITINGMultiple Locations, South Korea